Northern Trust Corp Theravance Biopharma, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 383,782 shares of TBPH stock, worth $3.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

383,782

Previous 464,967 17.46%

Holding current value

$3.78 Million

Previous $3.94 Million 21.54%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$7.66 - $10.25 $621,877 - $832,146	-81,185 Reduced 17.46%	383,782 $3.09 Million
Q2 2024 Aug 14, 2024	SELL	$8.29 - $9.92 $197,177 - $235,947	-23,785 Reduced 4.87%	464,967 $3.94 Million
Q1 2024 May 14, 2024	SELL	$8.22 - $11.59 $272,772 - $384,602	-33,184 Reduced 6.36%	488,752 $4.38 Million
Q4 2023 Feb 13, 2024	SELL	$8.58 - $11.4 $295,658 - $392,832	-34,459 Reduced 6.19%	521,936 $5.87 Million
Q3 2023 Nov 13, 2023	SELL	$8.38 - $10.44 $512,126 - $638,019	-61,113 Reduced 9.9%	556,395 $4.8 Million
Q2 2023 Aug 11, 2023	SELL	$10.16 - $11.92 $310,601 - $364,406	-30,571 Reduced 4.72%	617,508 $6.39 Million
Q1 2023 May 15, 2023	BUY	$9.87 - $11.44 $115,222 - $133,550	11,674 Added 1.83%	648,079 $7.03 Million
Q4 2022 Feb 13, 2023	BUY	$9.65 - $11.34 $367,684 - $432,076	38,102 Added 6.37%	636,405 $7.14 Million
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $25,748 - $31,365	3,069 Added 0.52%	598,303 $6.07 Million
Q2 2022 Aug 12, 2022	BUY	$8.41 - $10.34 $51,982 - $63,911	6,181 Added 1.05%	595,234 $5.39 Million
Q1 2022 May 13, 2022	SELL	$8.33 - $12.96 $210,815 - $327,991	-25,308 Reduced 4.12%	589,053 $5.63 Million
Q4 2021 Feb 08, 2022	BUY	$7.42 - $11.05 $86,984 - $129,539	11,723 Added 1.95%	614,361 $6.79 Million
Q3 2021 Nov 15, 2021	BUY	$6.77 - $14.41 $282,342 - $600,969	41,705 Added 7.43%	602,638 $4.46 Million
Q2 2021 Aug 13, 2021	BUY	$14.52 - $22.46 $605,527 - $936,649	41,703 Added 8.03%	560,933 $8.14 Million
Q1 2021 May 12, 2021	SELL	$16.57 - $21.08 $322,485 - $410,258	-19,462 Reduced 3.61%	519,230 $10.6 Million
Q4 2020 Feb 11, 2021	SELL	$14.89 - $20.16 $967,998 - $1.31 Million	-65,010 Reduced 10.77%	538,692 $9.57 Million
Q3 2020 Nov 16, 2020	SELL	$14.79 - $22.49 $438,168 - $666,288	-29,626 Reduced 4.68%	603,702 $8.93 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $230,301 - $342,439	11,158 Added 1.79%	633,328 $13.3 Million
Q1 2020 May 14, 2020	BUY	$17.84 - $31.21 $902,596 - $1.58 Million	50,594 Added 8.85%	622,170 $14.4 Million
Q4 2019 Feb 14, 2020	SELL	$16.12 - $25.89 $98,235 - $157,773	-6,094 Reduced 1.05%	571,576 $14.8 Million
Q3 2019 Nov 13, 2019	BUY	$16.51 - $23.78 $396,916 - $571,694	24,041 Added 4.34%	577,670 $11.3 Million
Q2 2019 Aug 13, 2019	BUY	$15.6 - $25.15 $55,333 - $89,207	3,547 Added 0.64%	553,629 $9.04 Million
Q1 2019 May 13, 2019	SELL	$22.57 - $28.15 $16,114 - $20,099	-714 Reduced 0.13%	550,082 $12.5 Million
Q4 2018 Feb 12, 2019	BUY	$22.52 - $35.07 $96,250 - $149,889	4,274 Added 0.78%	550,796 $14.1 Million
Q3 2018 Nov 14, 2018	BUY	$22.83 - $32.67 $256,563 - $367,145	11,238 Added 2.1%	546,522 $17.9 Million
Q2 2018 Sep 18, 2018	SELL	$22.06 - $25.52 $78,599 - $90,927	-3,563 Reduced 0.66%	535,284 $12.1 Million
Q2 2018 Aug 14, 2018	BUY	$22.06 - $25.52 $491,849 - $568,993	22,296 Added 4.32%	538,847 $12.2 Million
Q1 2018 May 09, 2018	BUY	$23.37 - $29.71 $105,375 - $133,962	4,509 Added 0.88%	516,551 $12.5 Million
Q4 2017 Feb 14, 2018	SELL	$25.82 - $35.66 $368,012 - $508,261	-14,253 Reduced 2.71%	512,042 $14.3 Million
Q3 2017 Nov 13, 2017	BUY	$23.88 - $34.96 $12.6 Million - $18.4 Million	526,295	526,295 $18 Million

Others Institutions Holding TBPH

# of Institutions

122

Shares Held

47.3M

Call Options Held

200

Put Options Held

12.8K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $658M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Theravance Biopharma, Inc. Transaction History